| Autor: |
Maher, TM, Swigris, JJ, Kreuter, M, Wijsenbeek, M, Axmann, J, Ireland, L, Nathan, SD |
| Zdroj: |
Thorax; 2017, Vol. 72 Issue: Supplement 3 pA246-A249, 4p |
| Abstrakt: |
IntroductionA majority of patients with IPF do not receive antifibrotic therapy with pirfenidone or nintedanib. We investigated viewpoints about IPF care and treatment amongst patients, and amongst physicians with a ‘watch and wait’ approach (WWP) or a proactive approach (PP).MethodsParticipants from Europe and Canada took part in an online survey. Responses were collected from patients with IPF, and from physicians responsible for initiation of IPF treatment who had consulted with ≥5 patients with IPF within 3 months. A mixture of WWP (monitor for ≥4 months post-diagnosis in ≥50% of patients before initiating antifibrotic) and PP (initiate antifibrotic <4 months post-diagnosis in majority of patients) were recruited.Results43 patients and 254 physicians were surveyed between September and October 2016. Only 56% of patients felt that they received enough information at diagnosis: 58% were advised that IPF is progressive; 44% discussed prognosis; and 49% were told about treatment options. Although the majority of patients (93%) preferred to receive information from their physician, most patients sought additional information about IPF (86%), treatment (81%), and/or prognosis (76%). Most patients (86%) felt that the ability of antifibrotic treatments to slow IPF progression was more important than side-effect profiles. Overall, 86% of patients who had received antifibrotic therapy felt confident in managing side effects. WWP were less likely to discuss IPF prognosis than PP, even when asked specifically by patients (Table). 62% and 38% of patients with ‘mild’ IPF were treated with an antifibrotic <4 months post-diagnosis by PP and WWP, respectively. WWP were more concerned about treatment side effects than PP (28% vs 17%, respectively); PP were more concerned about disease progression than WWP (83% vs 72%, respectively).ConclusionsWe identified a disparity between the information patients want at diagnosis and the information they receive from physicians. Furthermore, Results suggest that PP may be more confident with the benefit-risk profile of antifibrotic treatment than WWP. A belief in effective treatment options may aid conversation with patients regarding their IPF diagnosis, thereby enabling patients to make informed treatment decisions.Abstract M19 Table 1Differences between physicians regarding disease prognosis and treatment decisionsWWPn=118PPn=136Mention typical IPF prognosis at diagnosis 47% 59% Will avoid discussing typical prognosis/life expectancy even when patient asks 51% 33%* Comfortable discussing IPF prognosis 21% 34%* Strongly believe they can make a big difference in IPF patients’ lives post-diagnosis 29% 45%* Agree that antifibrotic therapies significantly slow the progression of IPF 36% 51%* Reasons for not treating patients with ‘mild’ IPF with an antifibrotic: Patient is asymptomatic/has few symptoms66% 36%* Patient has stable disease 65% 33%* Patient has good lung function 58% 38%* Patient has a good quality of life 53% 27%* Patient has IPF that is progressing slowly 53% 26%* *p<0.05 for PP vs WWP. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
